| Autor: |
Markman, Maurie, Saltz, Leonard B., Takimoto, Chris, Kruzelock, Russell |
| Zdroj: |
Colorectal Cancer (9781588297518); 2007, p263-279, 17p |
| Abstrakt: |
The advent of molecularly targeted therapies has fundamentally changed anticancer drug development. Advances in molecular oncology have altered scientific paradigms in drug discovery, and preclinical and early clinical drug development. In the current era, selective therapies are now rationally designed to inhibit specific novel targets that are well characterized at the molecular level. Inherent in this approach are new strategies that include testing agents in pharmacogenetically defined populations, analyzing the molecular profile of tumors prior to treatment, and individualizing anticancer therapy for each unique patient. Examples of promising molecular targets for future therapies for treating patients with colorectal cancer include the PI3K/Akt/mTOR signaling pathway and antiangiogenic inhibition, to name just two. This brief review discusses the new challenges and changing paradigms related to developing novel colorectal cancer therapeutics in the age of molecularly targeted therapies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
